Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Guardant360
MedTech
Guardant Health gets FDA nod to expand test for colon cancer
Guardant Health snagged the FDA green light to use its Guardant360 CDx colon cancer diagnostic along with Braftovi, cetuximab and chemotherapy.
Joseph Keenan
Jan 26, 2026 8:15am
Guardant360-guided breast cancer therapy swaps boost survival
Jun 3, 2025 10:00am
Guardant, Merck KGaA expand precision oncology collab
Aug 31, 2022 11:56am
FDA approves Guardant's next-gen, tumor-sequencing blood test
Aug 10, 2020 8:15am
Guardant blood test tracks MSI on par with tissue biopsy: study
Aug 5, 2019 9:30am
Resolution assay beats Guardant360 in complex gene fusion study
Apr 1, 2019 11:48am
